Today, February 23rd, 2026, Gilead Sciences announced a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, providing Gilead with full ownership of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for patients with relapsed or refractory multiple myeloma. Arcellx is a clinical-stage biotech company headquartered in Rockville, Maryland, founded in 2014. [Read more…]
Eli Lilly Commits Up to $2.4B to Orna Therapeutics in Major Bet on In Vivo CAR-T
In news announced yesterday (February 9, 2026), Eli Lilly revealed plans to acquire Orna Therapeutics for up to $2.4 billion, a truly staggering price tag. The move marks a decisive step toward the next generation of cell therapy: programming immune cells directly inside the patient rather than manufacturing them outside the body.
Importantly, this transaction is not centered on a single pipeline candidate, but on securing a platform technology that could reshape how CAR-T and other immune-reset strategies are developed and delivered across autoimmune disease and beyond. [Read more…]
CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide
CAR-T cell therapy is a type of immunotherapy that teaches T cells to recognize and destroy cancer. This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.
In this article:
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access
The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility.
GAITHERSBURG, Md., Nov. 6, 2025 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced the expansion of its LENTIVERSE™ platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company’s mission to make gene therapies more accessible and cost-effective for patients worldwide. [Read more…]
What is CAR-T Cell Therapy? A New Way to Treat Cancer
CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T cell therapy has demonstrated promising results in a range of patients across the globe. In some patients, this can lead to the total elimination of the cancer. In others, there is a significant improvement of the disease.
For those confronting cancer, one crucial question often arises: What is CAR-T cell therapy? This guide answers the most common questions and explains how this innovative technology is transforming the future of cancer treatment.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »